Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Clinical trial

Motion Delos: An Open Label Study to Investigate the Safety and Efficacy of Tradipitant in Participants Affected by Motion Sickness During Travel

ID
Name
VP-VLY-686-3403
Description
An open label study to investigate the safety and efficacy of tradipitant in participants affected by motion sickness during travel
Trial arms
Trial start
2023-02-27
Estimated PCD
2025-04-30
Trial end
2025-04-30
Status
Recruiting
Phase
Early phase I
Treatment
Tradipitant
Oral Capsule
Arms:
Tradipitant Dose A, Tradipitant Dose B
Size
500
Primary endpoint
Safety and tolerability of tradipitant as measured by reporting of adverse events (AEs).
through study completion, approximately 1 year
Eligibility criteria
Inclusion Criteria: * History of Motion Sickness * Age 18-75 Exclusion Criteria: * Nausea-inducing disorder other than motion sickness * BMI \> 40 * History of intolerance and/or hypersensitivity to Neurokinin-1 Receptor antagonists
Protocol
{'studyType': 'INTERVENTIONAL', 'phases': ['PHASE3'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 500, 'type': 'ESTIMATED'}}
Updated at
2024-03-21

1 organization

1 product

1 indication

Organization
Vanda Pharmaceuticals
Product
Tradipitant
Indication
Motion Sickness